Nucleix
PrivateLast Round
Series C
Extension
Dec 31, 2021
Total Funding Raised
$143.45M
Company Overview
Nucleix is a biotechnology company that develops non-invasive molecular diagnostic tests to enhance the accuracy and effectiveness of cancer detection through the use of DNA methylation patterns and proprietary biomarker assays.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleix Comparables
Compare Nucleix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pacific Edge Limited | 82% | |
| Pangea Laboratory | 81% | |
| MDxHealth | 78% |
Nucleix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Dec 31, 2021 | ||||
| Series C | Apr 7, 2021 | ||||
| VC Round | Jul 1, 2019 | ||||
| Grant | Jul 30, 2018 | ||||
| VC Round | May 23, 2016 | ||||
Grant | Mar 1, 2016 |
Key People
Founding team and executive leadership
Nucleix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aurum Ventures | Series C |
| DSC Investment | Series C Extension, VC Round, Series C |
| RA Capital Management | Series C Extension, Series C |
| European Commission (Horizon Europe) | Grant |
| LYFE Capital | Series C Extension, Series C |
| Gefen Capital | Series C |
| OrbiMed | VC Round, Series C Extension, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 25, 2025
Presenting Bladder EpiCheck data at the AUA 2025 conference.
- Dec 30, 2021
$22M round led by Sands Capital
Nucleix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nucleix's valuation, stock price, and market status.
Is Nucleix a public or private company?
Nucleix is a private company.
What is the current stock price of Nucleix?
Nucleix is a private company with no public stock price. No recent secondary market data is available.
How much is Nucleix worth (valuation)?
Valuation information for Nucleix is not publicly available.
Can I buy Nucleix stock?
Nucleix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nucleix's last funding round?
Nucleix's most recent funding round was Series C Extension on December 30, 2021.
Who are the main investors in Nucleix?
Key investors in Nucleix include RA Capital Management, OrbiMed, Aurum Ventures MKI, Sands Capital.
Will Nucleix IPO soon?
No public IPO plans have been announced for Nucleix.
How can I track Nucleix secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nucleix's secondary market activity and sign up for updates.